

Insurance Reimbursement Narrative

(Office Letterhead)

Insurance Company (Address)

Subject: Claim no., date and patient I.D., CDT-5 Code D0431: adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including pre-malignant and malignant lesions, not to include cytology or biopsy procedures.

On behalf of (patient I.D.):

The American Dental Association (ADA) has assigned CDT-5 code D0431 for adjunctive oral cancer screening. The establishment of this procedure code was based on the clinical efficacy^{2,3,4,5} and FDA approval of **ViziLite® Plus**, which is a diagnostic aid that helps oral healthcare professionals identify and mark abnormal oral lesions suspicious for pathology.

ViziLite® Plus enables me to visualize abnormal oral lesions, including pre-cancerous cells and cancer, which might be missed during my conventional oral cancer exam. In one clinical study it was demonstrated that ViziLite® Plus dramatically reduced the number of false positives lesions identified during conventional visual examination². In other studies, ViziLite® Plus identified abnormal lesions, including cancer, that were missed during conventional visual examinations^{3,4,5}. The ADA has stated that more than 25% of oral cancer victims do not use tobacco and have no other risk factors⁶. As such, I will be offering annual ViziLite® Plus exams to all my adult patients. Moreover, failure to diagnose oral cancer is the second most frequent reason dentists are sued with some plaintiff awards exceeding policy limits. Moreover, failure to diagnose oral cancer is the second most frequent reason dentists are sued with some plaintiff awards exceeding policy limits.

Please review the attached report of this procedure, including the mouth map used to document my conventional exam and the ViziLite® Plus exam. Should you need more clarification of the ViziLite® Plus technology, please feel free to contact me.

Sincerely,

¹ Multiple published clinical sources including:

1. FDA Web Site (www.fda.gov) accessed on April 2011; <http://www.fda.gov/cdrh/pdf/k003995.pdf>
2. Epstein JB, Silverman S, Epstein JD, et al. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and toluidine blue. *Oral Oncol.* 2008;44(6):615.
3. Huber MA DDS, Bsoul SA BDS, Terezhalmly GT DDS MA "Acetic Acid Wash and Chemiluminescent Illumination as an Adjunct to Conventional Oral Soft Tissue Examination for the Detection of Dysplasia: A Pilot Study" *Quintessence International* Volume 35, Number 5, May 2004
4. Epstein JB DMD, MSD, FRCD(C); Gorsky M DMD; Lonky SA MD, FACP, MBA; Silverman S Jr DDS. MA; Epstein JD MA; Bride MA DDS *The Efficacy of Oral Luminoscopy™ (ViziLite®) in Visualizing Oral Mucosal Lesions* Spec. Care Dentistry 26(4): 171-174, 2006
5. Kerr AR; Sirois DA; Epstein JB *Clinical Evaluation of Chemiluminescent Lighting: An Adjunct for Oral Mucosal Examinations* Journal of Clinical Dentistry 17:59-63, 2006
6. American Dental Association. *Oral health topics: Cancer, oral.* Available at: <http://www.ada.org/2607.aspx?currentTab=2>. Accessed April 14, 2010.